Zaripova 2012.

Study characteristics
Methods	Study design: parallel RCT Study duration: not reported Follow‐up duration: 6 months
Participants	Setting: single centre Country: Russia Relevant health status: CKD‐5D on HD Number: treatment group (36); control group (35) Mean age ± SD: 50.7 ± 9.4 years Sex (M/F); not reported Exclusion criteria: not reported
Interventions	Treatment group Spironolactone: 25 mg/day for 36 weeks Lisinopril and valsartan for 26 weeks (dose not reported) Control group Lisinopril and valsartan for 26 weeks (dose not reported)
Outcomes	LVM index
Identification	Authors name: Zaripova I Institution: not reported Email: not reported Address: not reported
Notes	Funding source: not reported Complete follow‐up: not reported Abstract‐only publication Complete follow‐up: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only states the study was randomised, does not ensure how sequence generation was done
Allocation concealment (selection bias)	Unclear risk	Only states the study was randomised, does not ensure how allocation concealment was done
Blinding of participants and personnel (performance bias) All outcomes	High risk	"Open‐label" study
Blinding of outcome assessment (detection bias) All outcomes	High risk	"Open‐label" study
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Complete follow‐up rate was not reported
Selective reporting (reporting bias)	Unclear risk	Not reported
Other bias	Unclear risk	Funding: not reported